Company Description
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.
It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases.
The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 16, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Anhco Nguyen |
Contact Details
Address: 1280 Rancho Conejo Blvd Thousand Oaks, California 91320 United States | |
| Phone | 805 623 4211 |
| Website | atarabio.com |
Stock Details
| Ticker Symbol | ATRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604464 |
| CUSIP Number | 046513107 |
| ISIN Number | US0465132068 |
| Employer ID | 46-0920988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anhco Nguyen Ph.D. | President, Chief Executive Officer and Director |
| Yanina Grant-Huerta | Chief Accounting Officer and Principal Accounting Officer |
| Alex Chapman | Vice President of Corporate Communications and Investor Relations |
| John Chao | Head of Legal |
| Jim Sesic | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2026 | EFFECT | Notice of Effectiveness |
| Mar 25, 2026 | 424B3 | Prospectus |
| Mar 17, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 16, 2026 | 424B5 | Filing |
| Mar 16, 2026 | 10-K | Annual Report |
| Mar 16, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 3, 2026 | 8-K | Current Report |